Prolactin prevents hepatocellular carcinoma by restricting innate immune activation of c-Myc in mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 31, 2014, Pages 11455-11460

  Hartwell, Hadley J ^a,b   Petrosky, Keiko Y ^c   Fox, James G ^d   Horseman, Nelson D ^e   Rogers, Arlin B ^a  

^a TUFTS UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Innate immunity; Lactotrophs; Liver neoplasms; Sex dimorphism

Indexed keywords

DOMPERIDONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1BETA; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROLACTIN; PROLACTIN RECEPTOR; PROTEIN KINASE B; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE ACTIVATION; GENE CONTROL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; INTRACELLULAR SIGNALING; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; TUMOR PROMOTION; UBIQUITINATION;

INNATE IMMUNITY; LACTOTROPHS; LIVER NEOPLASMS; SEX DIMORPHISM;

ADULT; ANIMALS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; DOMPERIDONE; FEMALE; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INTERLEUKIN-1BETA; LIVER; LIVER NEOPLASMS; MALE; MICE; MODELS, BIOLOGICAL; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROLACTIN; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MYC; RAS PROTEINS; RECEPTORS, PROLACTIN; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 4; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84905647862     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1404267111     Document Type: Article

References (50)

1. El-Serag HB (2012) Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142(6):1264-1273, e1.
2. Mucci LA, et al. (2001) Age at menarche and age at menopause in relation to hepatocellular carcinoma in women. BJOG 108(3):291-294. (Pubitemid 32210130)
3. Yu MW, et al. (2003) Role of reproductive factors in hepatocellular carcinoma: Impact on hepatitis B- and C-related risk. Hepatology 38(6):1393-1400.
4. Naugler WE, et al. (2007) Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317(5834):121-124. (Pubitemid 47056470)
5. Yang W, et al. (2012) Estrogen represses hepatocellular carcinoma (HCC) growth via inhibiting alternative activation of tumor-associated macrophages (TAMs). J Biol Chem 287(48):40140-40149.
6. Porsch Hällström I, Svensson D, Blanck A (1991) Sex-differentiated deoxycholic acid promotion of rat liver carcinogenesis is under pituitary control. Carcinogenesis 12(11):2035-2040.
7. Vekemans M, Robyn C (1975) Influence of age on serum prolactin levels in women and men. BMJ 4(5999):738-739.
8. Nagano M, Kelly PA (1994) Tissue distribution and regulation of rat prolactin receptor gene expression. Quantitative analysis by polymerase chain reaction. J Biol Chem 269(18):13337-13345.
9. Britschgi A, et al. (2012) JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: A rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell 22(6):796-811.
10. Jahn GA, et al. (1997) In vivo study of prolactin (PRL) intracellular signalling during lactogenesis in the rat: JAK/STAT pathway is activated by PRL in the mammary gland but not in the liver. Biol Reprod 57(4):894-900. (Pubitemid 27407211)
11. Le JA, et al. (2012) Generation of mice expressing only the long form of the prolactin receptor reveals that both isoforms of the receptor are required for normal ovarian function. Biol Reprod 86(3):86.
12. Telleria CM, et al. (1997) The different forms of the prolactin receptor in the rat corpus luteum: Developmental expression and hormonal regulation in pregnancy. Endocrinology 138(11):4812-4820. (Pubitemid 27460919)
13. Bridges RS, Scanlan VF, Lee JO, Byrnes EM (2011) Reproductive experience alters prolactin receptor expression in mammary and hepatic tissues in female rats. Biol Reprod 85(2):340-346.
14. Staib F, et al. (2014) CellMinerHCC: A microarray-based expression database for hepatocellular carcinoma cell lines. Liver Int 34(4):621-631.
15. Ferraris J, et al. (2012) Prolactin receptor antagonism in mouse anterior pituitary: Effects on cell turnover and prolactin receptor expression. Am J Physiol Endocrinol Metab 302(3):E356-E364.
16. Qazi AM, Tsai-Morris CH, Dufau ML (2006) Ligand-independent homo- and heterodimerization of human prolactin receptor variants: Inhibitory action of the short forms by heterodimerization. Mol Endocrinol 20(8):1912-1923. (Pubitemid 44148093)
17. Devi YS, et al. (2011) Inhibition of MAPK by prolactin signaling through the short form of its receptor in the ovary and decidua: Involvement of a novel phosphatase. J Biol Chem 286(9):7609-7618.
18. Negash AA, et al. (2013) IL-1β production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. PLoS Pathog 9(4):e1003330.
19. Rogers AB, et al. (2007) Hepatocellular carcinoma associated with liver-gender disruption in male mice. Cancer Res 67(24):11536-11546.
20. Theve EJ, et al. (2008) Sex hormone influence on hepatitis in young male A/JCr mice infected with Helicobacter hepaticus. Infect Immun 76(9):4071-4078.
21. Quinton LJ, et al. (2012) Hepatocyte-specific mutation of both NF-κB RelA and STAT3 abrogates the acute phase response in mice. J Clin Invest 122(5):1758-1763.
22. Fox JG, et al. (2010) Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. Gut 59(1):88-97.
23. Menon S, et al. (2012) Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice. Sci Signal 5(217):ra24.
24. Chen L, et al. (2007) Iron causes interactions of TAK1, p21ras, and phosphatidylinositol 3-kinase in caveolae to activate IkappaB kinase in hepatic macrophages. J Biol Chem 282(8):5582-5588. (Pubitemid 47093779)
25. Ninomiya-Tsuji J, et al. (2003) A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase. J Biol Chem 278(20):18485-18490. (Pubitemid 36799472)
26. Craig EA, Stevens MV, Vaillancourt RR, Camenisch TD (2008) MAP3Ks as central regulators of cell fate during development. Dev Dyn 237(11):3102-3114.
27. Schneider M, et al. (2012) The innate immune sensor NLRC3 attenuates Toll-like receptor signaling via modification of the signaling adaptor TRAF6 and transcription factor NF-κB. Nat Immunol 13(9):823-831.
28. Yamazaki K, et al. (2009) Two mechanistically and temporally distinct NF-kappaB activation pathways in IL-1 signaling. Sci Signal 2(93):ra66.
29. Korchnak AC, Zhan Y, Aguilar MT, Chadee DN (2009) Cytokine-induced activation of mixed lineage kinase 3 requires TRAF2 and TRAF6. Cell Signal 21(11):1620-1625.
30. Pineda G, Ea CK, Chen ZJ (2007) Ubiquitination and TRAF signaling. Adv Exp Med Biol 597:80-92.
31. Colak D, et al. (2010) Integrative and comparative genomics analysis of early hepatocellular carcinoma differentiated from liver regeneration in young and old. Mol Cancer 9:146.
32. Luo M, et al. (2013) Two-stage model of chemically induced hepatocellular carcinoma in mouse. Oncol Res 20(11):517-528.
33. Sandgren EP, Quaife CJ, Pinkert CA, Palmiter RD, Brinster RL (1989) Oncogene-induced liver neoplasia in transgenic mice. Oncogene 4(6):715-724. (Pubitemid 19150652)
34. Cruz-Soto ME, Scheiber MD, Gregerson KA, Boivin GP, Horseman ND (2002) Pituitary tumorigenesis in prolactin gene-disrupted mice. Endocrinology 143(11):4429-4436. (Pubitemid 35239577)
35. Hines IN, et al. (2011) Insulin resistance and metabolic hepatocarcinogenesis with parent-of-origin effects in AxB mice. Am J Pathol 179(6):2855-2865.
36. Yamamoto R, et al. (1995) Correlation between serum prolactin levels and hepatocellular tumorigenesis induced by 3′-methyl-4- dimethylaminoazobenzene in mice. Br J Cancer 72(1):17-21.
37. Furuta K, et al. (2008) Anti-tumor effects of cimetidine on hepatocellular carcinomas in diethylnitrosamine-treated rats. Oncol Rep 19(2):361-368. (Pubitemid 351176095)
38. Choi HK, Waxman DJ (1999) Growth hormone, but not prolactin, maintains, low-level activation of STAT5a and STAT5b in female rat liver. Endocrinology 140(11):5126-5135.
39. Stavreva DA, et al. (2009) Ultradian hormone stimulation induces glucocorticoid receptor-mediated pulses of gene transcription. Nat Cell Biol 11(9):1093-1102.
40. Sugathan A, Waxman DJ (2013) Genome-wide analysis of chromatin states reveals distinct mechanisms of sex-dependent gene regulation in male and female mouse liver. Mol Cell Biol 33(18):3594-3610.
41. Lu JC, Scott P, Strous GJ, Schuler LA (2002) Multiple internalization motifs differentially used by prolactin receptor isoforms mediate similar endocytic pathways. Mol Endocrinol 16(11):2515-2527. (Pubitemid 35266070)
42. Bigsby RM, Caperell-Grant A (2011) The role for estrogen receptor-α and prolactin receptor in sex-dependent DEN-induced liver tumorigenesis. Carcinogenesis 32(8):1162-1166.
43. LaPensee CR, et al. (2006) The prolactin-deficient mouse has an unaltered metabolic phenotype. Endocrinology 147(10):4638-4645. (Pubitemid 44402169)
44. Carré N, Binart N (2014) Prolactin and adipose tissue. Biochimie 97:16-21.
45. Horseman ND, et al. (1997) Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J 16(23):6926-6935. (Pubitemid 27520793)
46. Schuff KG, et al. (2002) Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms. J Clin Invest 110(7):973-981.
47. Yeh YT, Lee KT, Tsai CJ, Chen YJ, Wang SN (2012) Prolactin promotes hepatocellular carcinoma through Janus kinase 2. World J Surg 36(5):1128-1135.
48. Tao J, et al. (2014) Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice. Gastroenterology, 10.1053/j.gastro.2014.05.004.
49. Park JS, et al. (2014) JAK2-STAT3 blockade by AG490 suppresses autoimmune arthritis in mice via reciprocal regulation of regulatory T Cells and Th17 cells. J Immunol 192(9):4417-4424.
50. Rogers AB, Houghton J (2009) Helicobacter-based mouse models of digestive system carcinogenesis. Methods Mol Biol 511:267-295.